Trial Profile
A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 14 Apr 2023
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Murizatoclax (Primary)
- Indications Acute myeloid leukaemia; Multiple myeloma; Myelodysplastic syndromes
- Focus Adverse reactions; First in man
- Sponsors Amgen
- 16 Mar 2021 Status changed from active, no longer recruiting to discontinued.
- 15 Jan 2021 Status changed from recruiting to active, no longer recruiting.
- 19 Nov 2020 Planned number of patients changed from 90 to 160. Other primary endpoints of pharmacokinetic parameters added.